SCHEMBL4481010

SCHEMBL4481010

OCCCN1N=CC=Cc2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
CHRM1 P11229 1/20 0.39
DRD2 P14416 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
DRD1 P21728 1/20 0.39
PTGS1 P23219 1/20 0.39
SLC6A2 P23975 1/20 0.39
HTR2A P28223 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39
HRH1 P35367 1/20 0.39
OPRM1 P35372 1/20 0.39
DRD3 P35462 1/20 0.39
CACNA1B Q00975 1/20 0.39
SLC6A3 Q01959 1/20 0.39
KCNH2 Q12809 1/20 0.39
EBP Q15125 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11709130 0.83 MAPK1 (0.34) CHRM2HTR1AADRA2ACHRM1DRD2
SCHEMBL27574649 0.79 MEN1 (0.41) MAPK1MEN1KMT2ATDP1MTNR1A
SCHEMBL9471391 0.77 LMNA (0.34) MAPK1LMNATSHRSCN4ASCN5A
SCHEMBL7333680 0.76 P2RX4 (0.40) MAPK1MTNR1AMTNR1BLMNATSHR
SCHEMBL6610171 0.75 LMNA (0.45) MAPK1MTNR1AMTNR1BLMNATSHR
SCHEMBL27328961 0.74
SCHEMBL7492324 0.73 L3MBTL1 (0.34) ADRA1AKMT2ATDP1ALDH1A1LMNA
SCHEMBL28608699 0.71 LMNA (0.37) MAPK1MTNR1AMTNR1BLMNATSHR
SCHEMBL7061846 0.71 P2RX4 (0.34) CHRM2HTR1AADRA2ACHRM1DRD2
SCHEMBL6584861 0.69 ERCC5 (0.39) KMT2ASMN1; SMN2P2RX4P2RX1P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7498433-B2 Process and intermediates for the preparation of olanzapine KRKA, TOVARNA ZDRAVIL, D.D. (SI) 2009-03-03 US claimed
EP-1594879-B1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE KRKA TOVARNA ZDRAVIL D D NOVO (SI) 2008-10-22 EP claimed
US-20060040921-A1 Process and intermediates for the preparation of olanzapine KRKA, TOVARNA ZDRAVIL D.D. (SI) 2006-02-23 US claimed
EP-1594879-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE KRKA, tovarna zdravil, d.d., Novo mesto (SI) 2005-11-16 EP claimed
WO-2004065390-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF OLANZAPINE KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) 2004-08-05 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040921-A1 Process and intermediates for the preparation of olanzapine CYP4F11, CYP4A11, CYP3A4 CHRM2 1291/4885HTR1A 12/4885ADRA2A 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.